– USA, CA – Switch Therapeutics, a biotechnology company pioneering a new way to use RNA science to treat disease, utilizing its proprietary CASi platform, today announced the appointment of Dr. Doug Fambrough (Ph.D.) to its Board as an Independent Director.
About Dr. Douglas Fambrough
Dr. Fambrough was the Founder, President & CEO of Dicerna Pharmaceuticals, a pioneer in RNA Interference-based medicines that Novo Nordisk acquired for $3.3 billion in late 2021. Under his leadership of over ten years, the company optimized and perfected its GalXC RNAi technology, the foundation of nearly 20 drug development programs and six major corporate collaborations. Along the way, the company completed a highly successful IPO in 2014, trading on Nasdaq as DRNA. Before Dicerna, Dr. Fambrough was a General Partner with the venture capital firm Oxford Bioscience Partners, where he specialized in financing innovative life science companies with transformative technologies, twice appearing on the Forbes Midas list as the second highest ranked life science investor.
“I am honored to join the Switch Therapeutics Board of Directors and believe deeply in the promise of gene knockdown to address an array of unmet needs,” said Dr. Fambrough. “With CASi, Switch is advancing a novel class of drugs, with the potential to deliver cell selective RNAi activity, as well as efficient self-delivery and uptake, potency and durable gene knockdown. I believe this powerful technology could expand RNAi’s reach to potentially treat several central nervous system and systemic indications historically beyond the purview of RNAi-based medicine. I look forward to partnering with the Switch team to advance the company’s pipeline and, ultimately, deliver important new medicines that dramatically improve patients’ lives.”
Dr. Fambrough originally trained as a scientist, obtaining his Ph.D. in Genetics at the University of California, Berkeley, in 1996 before working as a genomic scientist at the Whitehead/MIT Center for Genome Research (now known as the Broad Institute).
About Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference science, to treat a ran to treat the central nervous system and systemic indications – with significant unmet needs. The CASi (Conditionally Aneedsated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School, and the City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell-selective RNAi activity. Switch is based in South San Francisco, California.
For more information: https://switchthera.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
